Elranatamab 用于治疗对其他干预难治的伴中枢神经系统受累的多发性骨髓瘤

Plasma cell leukemia and central nervous system involvement are two poor prognostic factors in myeloma, and such patients are often excluded from clinical trials. CASE: A 59-year-old patient with primary plasma cell leukemia developed leptomeningeal CNS disease following autologous transplant. Intrathecal chemotherapy and selinexor, pomalidomide, and dexamethasone failed to clear cerebrospinal fluid plasma cells. INTERVENTION: Elranatamab achieved complete serological and CNS response. The patient recovered from bedbound status to full independence and proceeded to receive CAR-T therapy. At 8 months post CAR-T, he remains in sustained MRD negativity.

Sequential bispecific antibody and CAR-T therapy demonstrates exceptional efficacy in CNS multiple myeloma, offering new hope for this historically terminal condition and supporting the systematic study of novel immunotherapies in high-risk myeloma populations. Trial Registration : The authors have confirmed clinical trial registration is not needed for this submission.